The remaining five are publicly available models to predict the status of clinical biomarkers (i.e., TP53, BRAF, MSI) as well as the risk of cancer death in kidney renal papillary cell carcinoma (KIRP) and glioblastoma-lower grade glioma (GMBLGG). This evidence concerns the gene TP53 and cancer.